Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapablursen in phlebotomy-dependent polycythemia vera
2021-003704-40Phase 2Terminated
- Sponsor
- Ionis Pharmaceuticals
- Start
- Dec 2022
- Modality
- Gene Therapies, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sapablursen in polycythemia vera (PV), sponsored by Ionis Pharmaceuticals. Primary endpoint: Reduction in the frequency of phlebotomy comparing baseline with the last 20 weeks of the 37-week treatment period. Started Dec 2022; status: terminated.
02
Drugs
sapablursen
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on 2021-003704-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003704-40.